**Supplementary Table 3. Adverse reactions among the study population, n (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| AEs | Treatment group(n = 197) | IHC control group(n = 221) | *p*-value |
| Neutropenia | 168(85.3) | 2(0.9) | < 0.001 |
| Thrombocytopenia | 171(86.8) | 2(0.9) | < 0.001 |
| Fever | 157(79.7) | 0(0) | < 0.001 |
| Headache | 126(64.0) | 0(0) | < 0.001 |
| Myalgia | 97(49.2) | 0(0) | < 0.001 |
| Fatigue | 174 (88.3) | 6(2.7) | < 0.001 |
| Anorexia | 113(57.4) | 3(1.4) | < 0.001 |
| Weight loss | 92(46.7) | 0(0) | < 0.001 |
| Alopecia | 71(36.0) | 0(0) | < 0.001 |
| Thyroid dysfunction | 16(8.1) | 0(0) | < 0.001 |
| Psychiatric abnormalities | 7(3.6) | 0(0) | 0.005 |
| ALT flares | 25(12.7) | 0(0) | < 0.001 |
| Rash | 10(5.1) | 0(0) | < 0.001 |
| Pruritus | 13(6.6) | 1(0.5) | < 0.001 |
| Antinuclear antibodies positive | 3(1.5) | 0(0) | 0.104 |
| Fundus hemorrhage | 2(1.0) | 0(0) | 0.222 |
| Nail lesions | 2(1.0) | 0(0) | 0.222 |

AEs, Adverse reactions; ALT, alanine aminotransferase.